FDA purge also requires giving up political influence of big money and big pharma. - no comment -
Personally, I am thrilled with the fact that Missling is working with Australia and we have a Parkinson's trial coming up in the EU, and Canada may also be in line for advancement of the 2-73 franchise - with or without the help of the FDA.
Missling is not putting all of our eggs in the FDA basket - too many holes!
There appears to be already be a positive consequence of the delay caused by waiting on the FDA and its new rules.
One of our posters has repeatedly posted that an AD trial will require 3000 subjects to move forward. He based that on solid historical precedent.
The company has said that the AD trial will require 300 subjects. I see that as a consequence of the new rules and the delays. We don't have a time line for the AD trial as of yet, but I can't see it being any longer than the historical precedent and it may well turn out to be shorter.
How much money did the company save by waiting and needing 300 instead of 3000 subjects? I'd call that a good move, even it is has delayed the start of testing.
News 
Market Data 
Discover 
AI
